Veracyte, Inc. (NASDAQ:VCYT) announced the launch of its Afirma Malignancy Classifiers to further establish the Afirma Thyroid FNA Analysis as a comprehensive tool for reducing unnecessary surgeries and healthcare costs among the more than 525,000 U.S. patients each year who undergo fine needle aspiration (FNA) biopsies to rule out cancer in thyroid nodules. Veracyte Inc. (NASDAQ:VCYT) weekly performance is -3.32%. On last trading day company shares ended up $12.82. Analysts mean target price for the company is $22.50. Veracyte Inc. (NASDAQ:VCYT) distance from 50-day simple moving average (SMA50) is -15.61%.
Trovagene, Inc. (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced that data from a study of its precision cancer monitoring technology, conducted by MD Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center, will be presented during a poster session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). TrovaGene Inc. (NASDAQ:TROV) shares fell -9.27% in last trading session and ended the day on $4.21. TROV gross Margin is – and its return on assets is -67.70%.TrovaGene Inc. (NASDAQ:TROV) quarterly performance is -34.01%.
NovaBay Pharmaceuticals Inc. (NYSEMKT:NBY) reported sales revenue of $188,000 for the quarter, as compared to $63,000 for the same quarter last year. NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) shares moved down -14.90% in last trading session and was closed at $0.834, while trading in range of $0.83 – $0.98. NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) year to date (YTD) performance is -32.20%.
Osiris Therapeutics Inc.’s (NASDAQ:OSIR) first quarter 2014 loss was 2 cents per share, a penny wider than the year-ago loss of 1 cent per share. However, first quarter 2014 loss was narrower than the Zacks Consensus Estimate of a loss of 8 cents per share. Osiris Therapeutics, Inc. (NASDAQ:OSIR) ended the last trading day at $16.37. Company weekly volatility is calculated as 9.78% and price to cash ratio as 9.49.Osiris Therapeutics, Inc. (NASDAQ:OSIR) showed a positive weekly performance of 15.36%.
Hemispherx Biopharma, Inc. (NYSE:HEB) announced that it has entered into a formal collaborative research agreement to test Alferon N Injection®, the only multi-species, natural alpha interferon commercially approved in the U.S. It will now be evaluated against wild type and Tamiflu® (oseltamivir)-resistant H7N9 influenza virus under the DEA (Data Exchange Agreement) Annex for Medical Preparedness and Bio-Defense Agreement between the Swiss Surgeon General and the US Department of Defense. Hemispherx BioPharma, Inc. (NYSEMKT:HEB) weekly performance is 6.63%. On last trading day company shares ended up $0.341. Analysts mean target price for the company is $3.00. Hemispherx BioPharma, Inc. (NYSEMKT:HEB) distance from 50-day simple moving average (SMA50) is -8.38%.